Elisabet de los Pinos, Aura's founder and CEO, will present a company overview at the 15th Annual Needham Healthcare Conference in New York, N.Y. The presentation will take place on Tuesday, April 12, 2016, at 2:40 p.m. EDT.
Laabs’ foundation and Aura Biosciences advance efforts to develop new and better therapies to treat rare cancer patients. Aura Biosciences is hoping to improve the options for future ocular melanoma patients.
We are Developing a New Class of Therapies to Target and Destroy Cancer Cells Selectively
Current treatments for cancers like ocular melanoma are highly invasive and often imprecise and toxic. We are creating a new class of therapies that can pinpoint solid tumors and metastases without harming surrounding tissue, enabling targeted treatment across a wide range of cancers.